Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand Posted May 19, 2021
Santen Establishes "Santen Vision for the Earth 2050" Setting Environmental Targets for 2030, Including CO2 Emissions Reduction Targets Posted May 18, 2021
Santen expresses a stance to strengthen its gender diversity. -Joining the "30% Club Japan," taking action to increase gender diversity at board and senior management -Becoming a signatory of the "UN Women's Empowerment Principles" promoting gender equality and women's empowerment in the workplace, marketplace and community Posted May 17, 2021
Notice of Postponement of "Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year" Posted May 11, 2021
Notice of Postponement of Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year Posted May 11, 2021
Santen has commenced the construction of the new factory in Suzhou to address expanding product demand in China -Toward reinforcing global production and supply structure- Posted Apr 22, 2021
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts Posted Apr 9, 2021
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts Posted Apr 9, 2021
Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean Posted Apr 6, 2021
Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year Posted Mar 12, 2021
Santen Recognized as One of Outstanding Enterprises in 2021 Certified Health and Productivity Management Outstanding Organization (Large Enterprise Category) Posted Mar 12, 2021
Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year Posted Feb 4, 2021
(Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year Posted Feb 4, 2021
Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension Posted Feb 2, 2021
Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea Posted Feb 1, 2021
Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference Posted Jan 8, 2021
Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities Posted Jan 7, 2021
